Investor Presentation First Nine Months of 2022

30 Investor presentation First nine months of 2022 Novo NordiskⓇ Pipeline supports significant growth opportunities across all four strategic focus areas PHASE 1 NN1845 - GSI NN1471 - Ideal Pump Insulin NN9041 - DNA Immunotherapy NN9541 Oral GLP-1/GIP co-agonist NN9917 - Sema Dapa FDC = NN9904 Once weekly oral sema NN9847 Oral Amycretin NN6020 - - DCR-AUD¹ Diabetes care PHASE 2 NN9389 FDC Sema - OW GIP NN9388 Cagrisema - NN9775 PYY 1875 analogue NN7533 NDEC NN7535- Etavopivat NN9931 Gilead NASH NN9500 FGF-21 NASH - - NN6021 = Belcesiran NN6019-ATTR Cardiomypathy Obesity care PHASE 3 NN1535 - Icosema NN1436 Insulin Icodec - - NN9924 Oral Semaglutide 25 and 50 mg NN9838 - Cagrisema NN9932 - Oral Semaglutide 50mg obesity² NN9931 Semaglutide NASH NN6535- Semaglutide in AD NN6018 Ziltivekimab - NN7769 Mim8 - Other PHASE 3 trials SOUL - Oral semaglutide 14.0 mg CVOT FOCUS Semaglutide 1.0 mg in diabetic retinopathy FLOW-Semaglutide 1.0 mg in chronic kidney disease - STRIDE Semaglutide 1.0 mg in peripheral arterial disease STEP Semaglutide 2.4mg in HFpEF SELECT - Semaglutide 2.4mg in obese population Rare blood disorders SUBMITTED - NN8640 Sogroya® - QW GHD³ APPROVED TresibaⓇ NN7415 Concizumab4 XultophyⓇ LevemirⓇ RyzodegⓇ NN7022 Nedosiran Rare endocrine disorders NovoMixⓇ FiaspⓇ NovoRapidⓇ RybelsusⓇ Ozempic Ⓡ6 VictozaⓇ WegovyⓇ SaxendaⓇ NovoSevenⓇ NovoEight® EsperoctⓇ NovoThirteenⓇ Refixia® NorditropinⓇ SogroyaⓇ5 Other serious chronic diseases 1 Dicerna-Alcohol Use Disorder; 225 mg trial also initiated; 3 Study conducted in growth hormone disorders; 4 Submitted to US/JP in HwI; 5 Approved in the EU, the US and Japan, for adult growth hormone disorder, 6 higher doses of injectable semaglutide (8 mg and 16 mg) tested in phase 2; PYY: Peptide YY; QW: Once-weekly; mAb: monocolonal antibody; GDF15: Growth differentiation factor 15; Sema: Semaglutide; FGF-21: Fibroblast growth factor 21; LAI: Long-acting insulin; GHD: Growth hormone disorder; GSI: Glucose Sensitive Insulin; HFPEF: heart failure with preserved ejection fraction; AD: Alzheimer's Disease; FDC; Fixed-dose combination; NASH: Nonalcoholic Steatohepatitis; US: United States; JP: Japan

View entire presentation